Serum to conduct clinical studies on proteins developed with Lipoxen's technology
Serum Institute of India will be conducting clinical studies on eight protein drugs including EPO, GCSF, Doxorubicin, flu and pneumococcal vaccines. These drugs have been developed using the patented polymer conjugation technology PolyXen and ImuXen provided by Lipoxen Technologies Ltd.
In PolyXen, the protein is conjugated with polysalic acid, increasing the molecular mass of the molecule. For ImuXen, used for DNA vaccines, the DNA of the virus (which produces the antigen) and the antigen itself are entrapped within Lyposomes. Both technologies enhance the life of the protein or a vaccine and protect it from degradation in blood.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.